Anadys Starts Hep C Trial
Luke Timmerman9/9/09
San Diego-based Anadys Pharmaceuticals (NASDAQ: ANDS) said today it has started a mid-stage clinical trial of its lead drug candidate, ANA598, for patients with hepatitis C. The study will enroll 90 patients on the drug or a placebo, in combination with the standard treatments—pegylated interferon alpha and ribavirin. Initial results on the anti-viral activity of the Anadys drug should be available by year-end, with more follow-up data to come in 2010, the company said. This ambitious trial design is part of what has brought Anadys back from some dark days earlier this year.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
